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Background: S100A12 is a member of the S100 family of 
calcium-binding proteins and is secreted either in inflamed 
tissues or in the bloodstream by activated neutrophils. 
Expression of S100A12 has been reported in various 
diseases, especially non-infectious inflammatory diseases, 
such as Kawasaki disease, giant cell arteritis and inflam-
matory bowel disease. Objective: This study was conducted 
to determine both the tissue expression and the serum levels 
of S100A12 in Behçet’s disease (BD) patients and the 
correlation of the S100A12 serum level with disease activity 
of BD. Methods: We included in this study ten BD patients 
who fulfilled the criteria for diagnosis, according to the 
International Study Group for BD. The activity of BD was 
calculated using the BD Current Activity Form. The serum 
concentrations of both S100A12 and interleukin-8 were me-
asured by the enzyme-linked immunosorbent assay, before 
and after treatment. Immunohistochemical studies were also 
performed to detect S100A12 expression in the skin. Results: 
The serum S100A12 level was significantly increased in the 
active BD period (p＜0.001), in the inactive BD period 
(p=0.041) and in patients with active Kawasaki disease 
(p=0.028), compared with the serum level in the healthy 
controls. The serum S100A12 level decreased significantly 
from baseline, compared to post-treatment (p=0.017). The 
activity score of BD was significantly correlated with the 
serum level of S100A12 (Spearman’s coefficient=0.464, 
p=0.039). Immunohistochemical studies showed that 
S100A12 was strongly expressed in the erythema nodo-
sum-like skin lesions of patients. Conclusion: S100A12 
contributes to the pathogenesis of BD related to neutrophil 
hyperactivity and reflects the disease activity in BD patients. 
(Ann Dermatol 23(3) 313∼320, 2011)
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INTRODUCTION
Behçet’s disease (BD), also known as Adamantiades-Beh-
çet’s disease, is a recurrent, multisystemic inflammatory 
disease characterized by recurrent oral aphthous and 
genital ulcers, ocular lesions, and skin lesions, and is 
occasionally accompanied by articular, urogenital, vas-
cular, gastrointestinal and neurologic system involve-
ment1-3. Although genetic factors, infectious agents and 
immunological mechanisms have all been implicated and 
studied, the etiology of BD still remains to be elucidated4. 
The role of hyperactive neutrophils is important in the 
pathogenesis of BD; histopathologic findings of show that 
the erythema nodosum-like lesions of BD are mainly 
composed of neutrophilic vascular inflammation, with 
accompanying changes in the subcutis5-7. Jorizzo et al.7 
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Table 1. Clinical details of Behçet’s disease (BD) patients in active period
Patient 
No.
Clinical findings Activity score S100A12 level
MU GU EN Pustule Arthralgia Arthritis AP A I A I
 1 ＋ ＋ ＋ ＋ ＋ ＋ − 6 1 1152±21 108±7
 2 ＋ ＋ ＋ − − − − 3 0 1202±15 608±10
 3 ＋ − ＋ − − − − 2 0  926±12  21±2
 4 ＋ ＋ ＋ ＋ ＋ − − 5 1  222±11 171±11
 5 ＋ ＋ ＋ ＋ ＋ − − 5 0  411±15 681±10
 6 ＋ − ＋ ＋ ＋ − − 4 1 1202±19 231±3
 7 ＋ ＋ ＋ − − − − 3 0 1146±25 321±14
 8 ＋ ＋ ＋ − − − − 3 1 1121±19 255±4
 9 ＋ − − ＋ − − ＋ 3 1  610±10 393±11
10 ＋ ＋ ＋ − − − − 3 0 1211±17 522±10
MU: mouth ulceration, GU: genital ulceration, EN: erythema nodosum, AP: abdominal pain, A: active BD period, I: inactive BD
period.
suggested that, during the evolution of these lesions, the 
lymphocyte-predominating reaction might follow a neut-
rophilic vascular reaction. Also, increased chemotaxis, 
phagocytosis, superoxide and lysosomal enzyme produc-
tion, as well as enhanced expressions of both CD11a and 
CD18 on the cell surfaces, have been reported in the 
neutrophils of BD patients8-10. These observations suggest 
that, in BD, the neutrophils are overactive and can 
eventually lead to tissue injury11,12.
S100A12, a newly identified extracellular receptor for 
advanced glycation end products-binding protein (EN- 
RAGE), is a member of the S100 family of calcium-binding 
proteins13. S100A12 is secreted either in inflamed tissues 
or in the bloodstream by activated neutrophils, and inte-
racts with the multi-ligand RAGE, as a receptor trans-
ducing proinflammatory signals, in the endothelial cells 
and cells of the immune system. S100A12 has been 
reported to have potent chemotactic activity, comparable 
with other chemotactic agents14,15. Binding of S100A12 to 
the extracellular domain of membrane RAGE activates an 
intracellular signal cascade, including the nuclear factor 
(NF)-κB, and induces secretion of cytokines, such as tumor 
necrosis factor-α (TNF-α)13,15-17. Thereby, S100A12 medi-
ates the proinflammatory effects on lymphocytes, endo-
thelial cells, neutrophils and mononuclear phagocytes13,18.
Expression of S100A12 has been reported in various disor-
ders, especially non-infectious inflammatory conditions, 
including Kawasaki disease (KD), inflammatory bowel 
disease (IBD), and giant cell arteritis19-22. Neutrophil infil-
tration and activation has been observed in the coronary 
artery lesions of KD, inflamed mucosa of IBD, and vasa 
vasorum within the adventitial layer of giant cell 
arteritis18-22. S100A12 is overexpressed at local sites of 
inflammation, and a high concentration of S100A12 can 
be found, during an active inflammatory episode13,18, in 
the serum, plasma, synovial fluid and stool. According to 
previous studies, in individual patients23, the S100A12 
level is a sensitive marker for monitoring both the disease 
activity and the response to treatment. Both the anti- 
S100A12 antibodies and soluble RAGE have been repor-
ted to suppress inflammatory reactions in the murine mo-
del of bovine serum albumin-induced hypersensitivity and 
chronic bowel inflammation24,25. However, to the best of 
our knowledge, the relationship between S100A12 and 
BD has not yet been described. The aim of our study was 
to determine both the tissue expression and the serum 
levels of S100A12 in BD patients. We also investigated, in 
BD patients, the changes in the serum levels of S100A12 
according to disease activity.
MATERIALS AND METHODS
Patients
We conducted this prospective pilot study following ap-
proval by the Institutional Review Board of Severance 
Hospital, Yonsei University College of Medicine, Seoul, 
Korea. A total of ten BD patients (mean age 38.6±9.2 
years; two male and eight female), who fulfilled the 
criteria for diagnosis from the International Study Group 
for BD, were enrolled in this study26. During study 
participation, all patients had been in the active period of 
the disease on their initial presentation, as demonstrated 
by fulfilling at least two of the following criteria, within 
four weeks of the study period: oral ulcer, genital ulcer, 
skin lesions, ocular lesions, arthritis, urogenital, vascular, 
gastrointestinal and neurologic system involvements. 
Patients were defined as being in the inactive period if 
they had none or one of the above criteria within four 
weeks. After the treatment, all patients were converted 
from the active to the inactive stage of BD. The activity of 
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BD was calculated using the BD Current Activity Form 2006 
(BDCAF; www.behcet.ws/pdf/BehçetsDiseaseActivityForm. 
pdf) and summarized in Table 1. The mean activity scores 
were separately evaluated in the baseline active period 
and in the inactive period, eight weeks after treatment. In 
the descending order of frequency, the following systemic 
treatments were delivered to the BD patients: colchicine 
(n=10), prednisolone (n=9), nonsteroidal anti-inflamma-
tory drugs (n=7), azathioprine (n=2), minocycline (n=1) 
and sulfasalazine (n=1).
The serum samples were separately collected from each 
patient, during the active and inactive periods of BD. In 
addition, the sera from ten patients with active KD (mean 
age 2.5±1.2 years; six male and four female) were 
obtained, as the disease control group. The diagnosis of 
KD was made by a pediatrician based on the fulfillment of 
at least five of the six diagnostic criteria for KD, as 
previously presented27. The sera of ten age- and sex-matched 
healthy individuals (mean age 37.2±8.1 years; two male 
and eight female) were also collected, as the normal 
control group. In five of ten BD participants with active 
BD, two to four days after the appearance of the skin 
lesions, biopsy specimens were taken for immun-
ohistochemical studies from the erythema nodosum-like 
skin lesions in the shin. The skin lesions were about 3∼6 
cm sized erythematous tender nodules. As a control 
group, buttock skin samples were obtained from five age- 
and sex-matched healthy volunteers, without any specific 
skin disease. Paraffin-embedded sections of the skin bio-
psies diagnosed as erythema nodosum (EN) were used, as 
previously described. Informed consent was obtained 
from all participants in this study.
Measurements of S100A12 and interleukin (IL)-8 con-
centrations
Serum S100A12 and IL-8 levels were evaluated before and 
after treatment. For determination of the serum S100A12 
and IL-8 levels, peripheral venous blood samples were 
drawn into vacutainer SST tubes (Becton Dickinson, 
Mountain View, CA, USA) and allowed to clot at room 
temperature (20oC to 24oC) for 30 minutes. The tubes 
were centrifuged at 1,000× g for ten minutes. The sera 
were then aliquoted and stored at −70oC, until used for 
testing. The serum S100A12 and IL-8 levels were 
determined (in duplicate) using commercial S100A12 
enzyme-linked immunosorbent assay (ELISA) kits (CycLex 
Co. Ltd., Nagano, Japan) and IL-8 ELISA kits (R&D Sys-
tems, Minneapolis, MN, USA). These procedures were 
performed according to the manufacturers’ instructions. 
Immunohistochemical studies
Paraffin-embedded sections of skin biopsies were used to 
detect S100A12 expression. Specimens were immediately 
fixed in 10% buffered formalin, dehydrated in ethanol, 
and embedded in paraffin. Commercially available puri-
fied mouse monoclonal anti-human S100A12 antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) was 
used in the immunohistochemical staining. The detailed 
procedures are, as follows. Prior to staining, tissue slides 
were de-paraffinized with xylene and re-hydrated in a 
graded series of ethanol, to remove the embedding media. 
Then tissue sections were pre-treated by boiling in 10 mM 
sodium citrate buffer (pH 6.0) in a microwave (95oC for 
two minutes), and washed and cooled in a phos-
phate-buffered saline (PBS) bath for 20 minutes. After 
washing, non-specific binding was blocked with 5% 
normal goat serum for 20 minutes. Then, tissue sections 
were incubated in a humidified chamber, with anti-human 
S100A12 antibodies for two hours at 4oC. After incubation 
with the primary antibody, sections were rinsed three 
times with PBS containing 0.05% Tween-20 for two mi-
nutes, and treated with biotin-conjugated secondary 
antibody for 30 minutes. After incubation with the secon-
dary antibody, sections were rinsed three times with PBS 
containing 0.05% Tween-20 for two minutes, incubated 
with alkaline phosphate conjugate for ten minutes, and 
rinsed in the same way. Then we applied HRP-streptavidin 
reagent to each section, incubated them for 30 minutes, 
rinsed them with distilled water containing 0.05% Tween- 
20, and stained them with hematoxylin for counter-stai-
ning. Finally, the specimens were dehydrated with gra-
dient alcohol and xylene and mounted with permanent 
mounting medium. 
Statistical analysis
The Mann-Whitney U test and Wilcoxon signed-rank test 
were performed to determine significant differences bet-
ween the distinct categories. Correlations were analyzed 
using the Spearman’s correlation coefficient. p-values of 
less than 0.05 were considered statistically significant. 
Statistical analyses were performed using the Statistical 
Product and Service Solutions program version 15 (SPSS 
Inc, Chicago, IL) for Windows.
RESULTS
Serum levels of S100A12
The serum level of S100A12 was significantly increased in 
the active BD period (median 1,134 ng/ml, range 373∼
1,211 ng/ml, p＜0.001), in the inactive BD period 
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Fig. 1. Serum levels of S100A12 in the active and inactive period
of Behçet’s disease (BD), in Kawasaki disease (KD) and in healthy
controls. The serum level of S100A12 was significantly in-
creased in BD patients in the active period (**p＜0.001), in BD
patients in the inactive period (*p＜0.05), and in KD patients
(*p＜0.05), compared with the serum levels of healthy controls.
Fig. 2. Comparison of serum S100A12 levels before and after
treatment in Behçet’s disease (BD) patients. Serum S100A12 
levels from ten BD patients were significantly decreased eight
weeks after systemic treatment (p=0.017). 
Fig. 3. Comparison between the activity score and the serum
S100A12 level in Behçet’s disease (BD) patients. The serum 
S100A12 level significantly correlated with disease activity 
(spearman’s coefficient=0.464, p=0.039).
Fig. 4. Serum levels of interleukin (IL)-8 in the active and inactive
periods of Behçet’s disease (BD), in Kawasaki disease (KD), and
in the healthy controls. Significantly increased serum IL-8 levels
were found in the sera from active BD patients (**p＜0.001),
but not in the sera from inactive BD patients or KD patients,
compared with the serum levels of healthy controls.
(median 299 ng/ml, range 21∼682 ng/ml, p=0.041), and 
in patients with active KD (median 356 ng/ml, range 54∼
1,677 ng/ml, p=0.028), compared to the serum level of 
the healthy controls (median 68 ng/ml, range 18∼442 
ng/ml) (Fig. 1). In the literature, mean serum S100A12 
levels of healthy controls ranged from 10 ng/ml to 75 
ng/ml13.
In BD patients, the median serum S100A12 level 
significantly decreased from 1,134 ng/ml (range 373∼
1,211 ng/ml) at baseline to 299 ng/ml (range 21∼682 
ng/ml) after treatment in the inactive BD disease state 
(p=0.017) (Table 1). However, one patient showed an 
increase in S100A12 even after treatment (Fig. 2). The 
mean activity scores, which were separately evaluated in 
the active period as baseline and, in the inactive period, 
eight weeks after treatment, were 3.7±1.3 (range 2∼6) 
and 0.5±0.4 (range 0∼1), respectively. The activity score 
was significantly correlated with the serum S100A12 level 
(Spearman’s coefficient=0.464, p=0.039) (Fig. 3).
Serum levels of IL-8 
Serum IL-8 was significantly increased in the active BD 
period (median 932 pg/ml, range 176∼2,207 pg/ml, p
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Fig. 6. Immunohistochemical staining with anti-S100A12 antibody
revealed strong expression of S100A12 in the polymorpho-
nuclear cell-infiltrated areas of panniculitis (A, B) and vasculitis 
(C) (original magnification, A: ×200, B, C: ×400).
Fig. 5. Comparison of the serum IL-8 levels before and after 
systemic treatments in ten Behçet’s disease (BD) patients 
revealed a decrease in the serum IL-8 level from baseline, 
although the change was not statistically significant (p=0.285).
＜0.001), but not in the inactive BD period (median 48 
pg/ml, range 11∼3,322 pg/ml, p=0.290), nor in KD 
patients (median 13 pg/ml, range 9∼300 pg/ml, 
p=0.436), compared to the serum levels of healthy 
controls (median 15 pg/ml, range 10∼208 pg/ml) (Fig. 4). 
In BD patients, after the treatment, the median serum IL-8 
level decreased from baseline to 48 pg/ml (range 11∼
1,132 pg/ml) at the inactive period, but the decrease was 
not statistically significant (p=0.285). Two patients even 
showed an increase in the serum IL-8 level after treatment 
(Fig. 5). The activity score was not significantly correlated 
with the serum IL-8 level (Spearman’s coefficient=0.285, 
p=0.110). There was no correlation between changes in 
serum IL-8 or S100A12 levels and systemic treatment 
modalities.
Immunohistochemical staining with anti-S100A12 anti-
body
Immunohistochemical analyses of biopsy specimens from 
five BD patients demonstrated strong reactivity with anti- 
S100A12 antibody in the cytoplasms of lymphohisto-
cytes, neutrophils, and endothelial cells, which all stained 
brown, whereas the cell nuclei were counterstained blue 
(Fig. 6). S100A12 was also distributed extracellularly, 
surrounding the anti-S100A12 antibody- reactive cells, 
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which suggests that it is a secreted protein. In all biopsies 
examined, the extent of reactivity differed between cases, 
but the staining pattern was similar. Although, some 
lymphohistiocytes expressed S100A12 in EN specimens, 
the expression level was weaker than in the erythema 
nodosum-like skin lesions of BD patients. Only sparse 
S100A12 expression was observed in biopsy specimens 
obtained from healthy control subjects.
DISCUSSION
Neutrophil infiltration is an important characteristic of the 
active phase of BD. However, the mechanism underlying 
the hyperactivity of neutrophils in BD has not been fully 
elucidated. According to previous reports, Th1-type cyto-
kines and chemokines, including IL-8, IL-17, TNF-α and 
interferon (IFN)-γ, have been suggested as a cause of 
neutrophilic hyperactivity28,29. Especially, elevated serum 
IL-8 levels have been demonstrated in BD patients30-32 
during the active phase of the disease.
Activated granulocytes secrete S100A12, which is also a 
strong chemotactic factor for other leukocytes13,17-19,21. In 
the present study, analysis of S100A12 in both erythema 
nodosum-like skin lesions and sera indicated that S100-
A12 is expressed and secreted at local sites of inflam-
mation. Infiltration of S100A12-positive polymorphonu-
clear cells is supposed to be an early step in the inflam-
mation process, prior to invasion of mononuclear cells. 
Ligation of RAGE by S100A12 activates NF-κB and 
proinflammatory cytokines, including TNF-α, IL-2 and 
IL-613,18,33. In BD patients13,33, NF-κB activation may 
protect T cells against apoptosis, via expression of 
anti-apoptotic genes. It has been demonstrated that TNF-
α, which is observed in high amounts in both skin lesions 
and sera of BD patients, stimulates S100A12 secretion in 
peripheral neutrophils, and also induces NF-κB activa-
tion29,34-37. Therefore, TNF-α and S100A12 are suggested 
to constitute a positive inflammatory feedback loop18. 
S100A12 has been shown to enhance the expressions of 
adhesion molecules on endothelial cells, including 
ICAM-1 and VCAM-117,18. In BD patients, some studies 
have reported that the expressions of ICAM-1 and 
VCAM-1 on the endothelial cells are increased, which is 
associated with enhanced endothelial adhesion properties 
of both mononuclear cells and neutrophils38,39. 
The role of IL-8 in BD has been demonstrated in several 
investigations. IL-8 is a potent chemoattractant and acti-
vator of neutrophils26. Some studies in BD patients31-33 
have shown increased serum levels of IL-8 that were 
correlated with disease activity. However, other contradic-
tory results have indicated that IL-8 levels were not related 
to disease activity in BD patients40,41. In the present study, 
serum IL-8 was significantly increased in active BD, but 
not in the inactive BD period, compared with controls. 
Although the serum IL-8 levels decreased after systemic 
treatment, the change was not statistically significant, and 
serum IL-8 concentrations were not correlated with the 
activity score. Based on this finding, we concluded that, in 
our study population, S100A12 was a better indicator of 
BD activity than IL-8. 
There have been few reports on the role of IL-8 in KD, 
although neutrophils may be early effector cells for 
vascular endothelial damage in the acute phase of KD. Lin 
et al.42 reported that the elevated serum IL-8 level during 
the first week of illness may be associated with a higher 
risk of coronary aneurysm formation. However, Suzuki et 
al.43 found no significant differences in the serum IL-8 
levels, before and after intravenous immunoglobulin 
treatment. Moreover, Asano and Ogawa44 revealed that the 
plasma level of IL-8 was elevated in the acute phase of KD, 
compared with that of healthy controls, though the 
difference was not statistically significant. In our study, a 
significant increase in the serum S100A12 level was 
observed in both BD and KD patients, and the serum IL-8 
level was also significantly increased in active BD. 
However, the serum IL-8 level was not significantly incre-
ased in patients with KD, compared with that of the 
controls, although neutrophilic vasculitis is a common 
finding in both BD and KD. An elevated serum 
concentration of S100A12 in KD patients has been shown 
to be correlated with inflammatory disease activity19,20. 
Also, in the present study, we demonstrated that elevated 
serum levels of S100A12 in BD patients were correlated 
with the BDCAF scores. However, one patient showed a 
paradoxical increase in S100A12, even after converting to 
the inactive phase by the treatment. It has been previously 
reported that serum S100A12 levels of some KD patients 
increased after intravenous immunoglobulin treatment19. 
Intracellular S100A12 levels of neutrophils in these KD 
patients were low19. Delayed elevation of the serum 
S100A12 may be caused by intracellular depletion, alth-
ough we did not check the intracellular S100A12 levels of 
that BD patient. Other cytokines, such as TNF-α, may 
influence the delayed secretion of S100A12. To elucidate 
our hypothesis, both intracellular S100A12 staining and 
ex vivo neutrophil stimulation with TNF-α should be 
performed. 
In conclusion, we demonstrated that S100A12 serum levels 
are increased in BD patients, and we performed 
immunohistochemical studies to reveal S100A12 expression 
patterns in specimens of erythema nodosum-like skin lesions 
from active BD patients. Our results indicate that S100A12 
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may have a pathogenic role related to neutrophil hyperac-
tivity in BD patients, and therefore, serum levels of S100A12 
may indicate disease activity in BD patients. However, 
because our pilot study only included ten BD patients, we 
need to further investigate the pathogenic role of S100A12 in 
BD in a larger sample of BD patients.
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